Regulatory B Cells in Inflammatory Rheumatisms and Biomarkers of Response to Biologic Treatments

University Hospital Center (CHU)

Status: Unknown

Conditions: Osteoarthritis; Sjogren's Syndrome; Spinal Disease; Scleroderma; Spondylitis; Systemic Lupus Erythematosus; Chondrocalcinosis; Gout; Rheumatoid Arthritis

Study type: Observational

Funder types: Other

Identifiers

NCT01642706

8969

Details and patient eligibility

About

B cells are known to play an important role in auto-immune diseases by activating T cells, secreting inflammatory cytokines and autoreactive antibodies. However, a sub-type of B cells named regulatory B cells or Bregs has recently shown capacities to prevent or cure arthritis in mouse models. Bregs have also been identified in humans.

Full description

B cells are known to play an important role in auto-immune diseases by activating T cells, secreting inflammatory cytokines and autoreactive antibodies. However, a sub-type of B cells named regulatory B cells or Bregs has recently shown capacities to prevent or cure arthritis in mouse models. Bregs have also been identified in humans. Main objective: To study Bregs abnormalities in patients with rheumatoid arthritis (RA) at different stages of the disease compared to subjects with mechanical pathologies.Secondary objectives:- To evaluate the specificity of any abnormalities identified in RA by studying Bregs in patients with other autoimmune or other inflammatory joint diseases.- To evaluate the effect of biological and synthetic treatments on Bregs in patients with RA. - To assess whether the rate of Bregs before treatment is predictive of response to biological and synthetic treatments.

Enrollment: 240 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

For RA patients and control patients:

• Age over 18 year old
• Blood sample taken as part of the usual management
• Steroid less than or equal to 15 mg/day and stable for at least a week

For RA patients:

• Patient with RA meeting the ACR / EULAR 2010

For control patients:

• Patients with systemic autoimmune disease (lupus, Sjogren's syndrome, scleroderma) or other inflammatory arthritis (spondylitis, crystals) or a mechanical pathology (limb osteoarthritis or spinal pathology) .

Exclusion criteria

• steroids over 15 mg/day
• rituximab infusion in less than 12 months

Trial design

240 participants in 2 patient groups

RA patients

Description:

Patients affected by Rheumatoid arthritis.

Control

Description:

Subjects affected by either : * mechanical pathology * systemic auto-immune pathology * other inflammatory rheumatism